Biomarker-guided personalized therapies oer great promise to improve drug development and improve patient care, but also pose dicult challenges in designing clinical trials for the development and validation of these therapies. We rst give a review of the existing approaches, briey for clinical trials in new drug development and in more detail for comparative eectiveness trials involving approved treatments. We then introduce new group sequential designs to develop and test personalized treatment strategies involving approved treatments.
Introduction
The development of imatinib (Gleevec), the rst drug to target the genetic eects of chronic myeloid leukemia (CML) while leaving healthy cells unharmed, has revolutionized the treatment of cancer, leading to hundreds of kinase inhibitors and other targeted drugs that are in various stages of development in the anticancer drug pipeline. However, most new targeted treatments have resulted in only modest clinical benet, with less than 50% remission rates and less than one year of progression-free survival. While the targeted treatments are devised to attack specic targets, the one size ts all treatment regimens commonly used may have diminished their eectiveness. In contrast, trastuzumab (Herceptin), which treats only patients with HER-2 positive metastatic breast cancer, has better remission rate and longer progressionfree survival because it targets the right patient population. Genome-guided and risk-adapted personalized therapies of this kind are expected to substantially improve the eectiveness of these treatments.
Although personalized therapies that are tailored for individual patients have great promise to improve drug development and patient care, there are challenges in designing clinical trials for the development and validation of these therapies because traditional trial designs often require large sample sizes that far exceed practical constraints on funding and study duration. Adaptive designs have been proposed to overcome these challenges in new drug development for regulatory approval. There are two important preliminaries in designing a phase III clinical trial for such drugs. One is to identify the biomarkers that are predictive of response, and the other is to develop a biomarker classier that identies patients who are sensitive to the treatment, denoted Dx+. An example is Herceptin, for which strong evidence of the relationship between the biomarker, HER2, and the drug eect was found early and led to narrowing the patient recruitment to HER2-positive patients in the phase III trial. In the ideal setting that the biomarker classier can partition the patient population into drug-sensitive (Dx+) and drug-resistant (Dx-) subgroups, it is clear that Dxpatients should be excluded from the clinical trial. In practice, however, the cut-point for the Dx+ group is often based on data from early phase trials with relatively small sample sizes and has substantial statistical uncertainty (variability). Thus, a dilemma arises at the design stage of the phase III trial. Should the trial only recruit Dx+ patients who tend to have larger eect size, or should it have broad eligibility from the entire intended-to-treat (ITT) patient population but a diluted overall treatment eect size? The former has the disadvantage of an overly stringent exclusion criterion that misses a large fraction of patients who can benet from the treatment if the classier imposes relatively low false positive rate for Dx+ patients, while the latter has the disadvantage of ending up with an insignicant treatment eect by including patients that do not benet from the treatment. To address this dilemma in the context of a phase III trial with a time-to-event endpoint, Brannath et al. [1] propose a two-stage trial design, in which the selection of the ITT or Dx+ population is performed based on conditional power at the rst interim analysis. For the nal analysis, a weighted combination of the second-stage p-value (based on the second-stage data) and the rststage p-value, together with Simes' step-up procedure [2] to adjust for multiple testing, are used to ensure that the adaptive test maintains the prescribed type I error of the phase III trial. Jenkins et al. [3] extend the design of Brannath et al. to a phase II-III trial in which the phase II trial has a short-term survival endpoint that is used to select the ITT or Dx+ population for the phase III trial with a long-term survival endpoint. Earlier Wang et al. [4] have introduced a similar design for normally distributed outcomes. The basic idea underlying these adaptive designs is to use a weighting scheme of the form S 1 + γS 2 that combines the rst-stage and second-stage test statistics S 1 and S 2 or to choose the critical value of the Studentized second-stage statistic as some function of that of the rst-stage to preserve the type I error probability; see The main focus of this paper is on designing clinical trials for the development and validation of personalized therapies based on approved cancer treatments, which usually have well-understood molecular targets, mechanisms of action, and mechanisms of resistance. It is natural to try to use this information in con-junction with the patient's biomarkers that can predict sensitivity or resistance to the treatments, thereby developing a biomarker-guided strategy (BGS) to personalize treatment selection for the individual patients.
After a review of previous methods in the literature, we introduce new group sequential designs in Section 2. Statistical inference in these designs is also discussed, and Section 3 demonstrates their advantages in simulation studies after providing implementation details. Section 4 gives further discussion and concluding remarks.
2. Development and Validation Trials for Biomarker-Guided Personalized Therapies 2.1. Review of existing approaches Simon [6] has considered the development of biomarker classiers for treatment selection and the design of validation trials for comparing a BGS to standard of care (SOC) that does not use the biomarkers to select treatments. For the validation trial, which he regards as an analog of a phase III trial, he shows that the biomarker-strategy design which randomizes patients to BGS and SOC is inecient and proposes an enrichment design as an alternative. He also points out that development studies of the BGS are often based on a convenience sample of patients for whom tissue is available but who are heterogeneous with regard to treatment and stage, and have the goal of developing a genomic classier and evaluating its predictive accuracy by split-sample methods or cross-validation. The estimated predictive accuracy can be used to determine whether the classier is promising and worthy of phase III evaluation, analogous to phase II clinical trials. A diculty with this approach is that the convenience sample comes from observational studies which have no specic eligibility criteria, no primary endpoint or hypotheses and no dened analysis plan, but which often involve multiple biomarkers to evaluate, multiple ways of measuring and combining the candidate biomarkers. Although it would be desirable to base the development of BGS on data from well designed clinical trials, it is dicult to obtain funding for such trials in practice. On the other hand, if the estimated predictive accuracy for the BGS developed from the convenience sample shows promise, then it may be possible to obtain funding for the validation trial. This is similar to phase I and II cancer trials that are single-arm and limited to relatively small sample sizes. Only after the phase II trial provides signicant results showing that the new treatment has better response rate than some historical control rate can a randomized phase III trial with a survival endpoint be conducted. The limitations of these designs are discussed by Lai et al. [7] who point out in particular that the data that suggest the BGS are preliminary and do not provide a uniform level of condence in the recommendations made in each stratum.
Recognizing these limitations of the BGS developed, Lai et al. [7] propose to test in the validation trial not only the strategy null hypothesis dened by the BGS but also an intersection null hypothesis is not rejected, the biomarker strategy that rejects H 0 would guide further development. In this way, the validation trial can be used not only to test the BGS but also to continue learning biomarker strategies from the clinical trial data. The strategy null hypothesis is H * 0 :
, where π j is the prevalence of subgroup j, P j is the average response of patients in subgroup j to the treatment recommended by the BGS andq j is that to the treatments not recommended by the BGS, which is what an enrichment design attempts to test. As pointed out by Lai et al. [7] , H * 0 represents a hypothetical version of SOC that assumes equal probabilities of choosing the K treatments in a biomarker subgroup, lacking a true representation of a physician's choice condition.
Mandrekar and Sargent [8] give a review of designs of clinical trials for predictive biomarker validation in the context of real trials, and discuss their merits and limitations. In particular, they consider the biomarker-stratied design that randomizes patients to treatments within each biomarker class and focuses on the treatment-marker interaction in the analysis plan, with the MARVEL (marker validation of erlotinib in lung cancer) study as an example for which the sample size is prospectively specied separately for each biomarker class. They also describe prospectively specied analysis of data from a previously conducted RCT comparing treatments, but point out that while a well conducted retrospective validation study may be accepted as a marker validation strategy in certain instances, the gold standard for predictive marker validation continues (appropriately) to be a prospective RCT.
A Bayesian alternative to frequentist testing of BGS is described by Zhou et al. [9] and Lee et al. [10] for the BATTLE (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination) trial of personalized therapies for non-small cell lung cancer (NSCLC). As pointed out by [11, pp. 45-46] concerning the biomarker classiers, the signaling pathways and targeted agents were selected on the basis of the highest scientic and clinical interest at the time (2005) and included EGFR mutation/copy number amplication, KRAS/BRAF mutation, VEGF/VEGFR expression and RXR/CyclinD1 expression, together with the recommended targeted agent for each; see Fig. 1 and refs. 9-12 of [11] . Although this provides a BGS similar to Simon's framework, the BATTLE trial uses an adaptive randomization scheme to select K = 4 treatments for n = 255 NSCLC patients belonging to J = 5 biomarker classes, one of which contains patients whose biomarker scores are all negative. Let y mjk denote the indicator variable of disease control, which is dened by progression-free survival at 8 weeks after treatment, of the mth patient in class j receiving treatment k. The adaptive randomization scheme is based on a Bayesian probit model for p jk = P (y mjk = 1) = P (ξ mjk > 0), where ξ mjk is assumed to be a latent normal random variable with variance 1 and mean µ jk ∼ N [9] have noted that one known ramication of the AR design is that it results in biased estimates due to dependent samples. The overall 8-week disease control rate (DCR) using the biomarker-guided AR scheme was 46%, compared to the historical 30% DCR estimate in similar patients (ref. 14) , showing that the learn-as-we-go approach in Bayesian AR can indeed leverage accumulating patient data to improve the treatment outcome by allowing more patients to be assigned to more eective therapies and fewer patients to be assigned to less eective therapies.; see [11, pp. 46, 52] .
Note that unlike Simon's enrichment design that randomizes patients to SOC and the BGS to be validated, the BATTLE design aims at showing that the AR treatment assignment has higher DCR than some historical estimate of the DCR of SOC. In their discussion, Kim et al. [11, pp. 49-50 ] describe what they have learned from the BATTLE trial for a future BATTLE-2 trial, which will use EGFR mutations rather than EGFR mutation/copy number to narrow the biomarker subgroup because EGFR mutations were far more predictive and which will not use RXR that had little, if any, predictive value in optimizing treatments.
In their framework, AR provides a design for simultaneously treating patients with a given set of approved targeted agents based on the patients' biomarker proles, and learning the treatment allocation rule from accumulating data.
The preceding paragraph shows that the BATTLE and BATTLE-2 trials share the philosophy of the classical multi-arm bandit problem. Suppose there are K treatments of unknown ecacy to be chosen sequentially to treat a large class of n patients. How should we allocate the treatments to maximize the mean treatment eect? Lai and Robbins [12] and Lai [13] consider the problem in the setting where the treatment eect has a density function f (x; θ k ) for the kth treatment, where the θ k are unknown parameters. There is an apparent dilemma between the need to learn the unknown parameters and the objective of allocating patients to the best treatment to maximize the total treatment eect S n = X 1 +· · ·+X n for the n patients. If the θ k were known, then the optimal rule would use the treatment with parameter θ
where µ (θ) = E θ (X). In ignorance of θ k , Lai and Robbins [12] dene the regret of an allocation rule by
where T n (k) is the number of patients receiving treatment k. They show that adaptive allocation rules can be constructed to attain the asymptotically minimal order of log n for the regret, in contrast to the regret of order n for the traditional equal randomization rule that assigns patients to each treatment with equal probability 1/K. A subsequent renement by Lai [13] shows the relatively simple rule that chooses the treatment with the largest upper condence bound U (n) k for θ k to be asymptotically optimal if the upper condence bound at stage n, with n > k, is dened by
where inf ∅ = ∞, A is some open interval known to contain θ,θ k is the maximum likelihood estimate of θ k .
I (θ, λ) is the Kullback-Leibler information number, and the function h has a closed-form approximation.
For the rst K stages, the K treatments are assigned successively. It is noted in [14, p. 97 ] that the upper condence bound U (n) k corresponds to inverting a generalized likelihood ratio (GLR) test based on the GLR
An adaptive design combining multiple objectives
The multi-arm bandit problem has the same learn-as-we-go spirit of the BATTLE trial and focuses on attaining the best response rate for patients in the trial. However, such a trial does not establish which treatment is the best for future patients, with a guaranteed probability of correct selection. We now describe a group sequential design for jointly developing and testing treatment recommendations for biomarker classes, while using multi-armed bandit ideas to provide sequentially optimizing treatments to patients in the trial.
Thus, the design has to fulll multiple objectives, which include (a) treating accrued patients with the best (yet unknown) available treatment, (b) developing a treatment strategy for future patients, and (c)
demonstrating that the strategy developed indeed has better treatment eect than the historical mean eect of SOC plus a predetermined threshold. In a group sequential trial, sequential decisions are made only at times of interim analysis. Let n i denote the total sample size up to the time of the ith analysis, i = 1, · · · , I, so that n I is the total sample size by the scheduled end of the trial, and let n ij be the total sample size from biomarker class j up to the time of the ith analysis, hence n i = ∑ J j=1 n ij . Because of the need for informed consent, the treatment allocation that uses the aforementioned upper condence bound rule is no longer appropriate. It is unlikely for patients to consent to being assigned to a seemingly inferior treatment for the sake of collecting more information to ensure that it is signicantly inferior (as measured by the upper condence bounds). Instead, randomization in a double blind setting is required, and the randomization probability π
jk , determined at the ith interim analysis, of assigning a patient in group j to treatment k cannot be too small to suggest obvious inferiority of the treatments being tried, that is,
We now describe the adaptive randomization rule. The unknown mean treatment eect µ jk of treatment k in biomarker class j can be estimated by the sample meanμ ijk at interim analysis i.
which can be estimated byk ij = arg max kμijk at the ith interim analysis. Analogy with multi-arm bandit theory suggests assigning the highest randomization probability to treatmentk ij and randomizing to the other available treatments in biomarker class j with probability ϵ. Because the randomization probabilities are only updated at interim analyses in a group sequential design and becausek ij may uctuate over i among treatments whose treatment eects do not dier by more than δ ij , it is more stable to lump these nearby treatments into the set
whereμ * ij =μ ijkij and K ij is the set of available treatments in biomarker class j at interim analysis i. The randomization probabilities π
jk are therefore determined at the ith interim analysis by
where we use |A| to denote the number of elements of a nite set A. Equal randomization is used up to the rst interim analysis. In Section 3.1, we carry out a simulation study of the performance of this design for the objective of treating patients in the trial with the best available treatments, and compare it with an alternative adaptive randomization scheme proposed by Zhou et al. [9] for the BATTLE trial and modied by Lai et al. [7] .
Besides treating patients in the trial with the best available treatment, the group sequential design can also be used to address testing and inference questions, with guaranteed error probabilities, that are of basic interest to personalized treatment selection for future patients based on their biomarkers. We use GLR statistics and modied Haybittle-Peto stopping rules introduced by Lai and Shih [15] to include early elimination of signicantly inferior treatments from a biomarker class. Following [13] and [15] , we assume an exponential family of distributions for the treatment eects, with density function f θ (x) = e θx−ψ(x) with respect to some probability measure ν on Θ = { θ :´e θx dν (x) < ∞ } , where θ depends on the treatment k and biomarker class j and will be dened by θ jk . In the exponential family, the mean µ is ψ ′ (θ) and 
Let n ijk be the total sample from biomarker class j receiving treatment k up to the ith interim analysis, so and plays a basic role in constructing the upper condence bound rule in the multi-arm bandits from the exponential family.
We now propose an elimination scheme based on the GLR statistic (3) with a guaranteed probability of 1 − α that the best for each biomarker class is not eliminated. At the ith analysis (
The computation of a α is described in Section 3.2. This elimination scheme is also related to the second objective of the trial, which is inference, at the end of the trial, on which treatment strategy is best for future patients. To accomplish the above objective, we use subset selection ideas from the selection and ranking literature [16, 17] , in which there are two approaches to selecting the best of K treatments with guaranteed probability of correct selection.
One is the indierence zone approach, which guarantees that the probability of correctly selecting the best treatment exceeds 1−α when the largest mean eect diers from the second largest by at least δ. In practice, however, one does not have any idea about the distance between the largest and second largest means. To address this diculty, Chan and Lai [18] consider a stronger constraint that the probability of selecting a treatment whose mean eect is within δ of the largest is at least 1 − α. They also develop an ecient fully sequential procedure to attain this. Their procedure, however, cannot be extended to a group sequential design in which there is a prescribed upper bound on the total number of observations. An alternative to the indierence zone approach is subset selection, for which the goal is to select a subset of treatments, with a guaranteed probability of at least 1 − α that it contains the best treatment. In this approach, one also wants the expected size of the selected subset to be as small as possible in some sense.
We extend the subset selection approach to the setting of J biomarker classes in a group sequential design. Using the elimination scheme described in the proceeding paragraph, let K ij be the set of surviving treatments for class j at the ith interim analysis. When K ij consists only ofk ij , the trial recommends using treatmentk ij for future patients. For notational simplicity, K Ij at the Ith analysis by the trial's scheduled end will be denoted by K j , which may contain two or more treatments. Similarly we denoteμ Ijk byμ jk .
The recommended set of treatments for class j is K j , with an overall probability guarantee of 1−α to contain the best treatments for all classes. Whereas the probability α of incorrectly eliminating the best treatment in subset selection corresponds to type I error in hypothesis testing,
is an analog of traditional type II error, where B j
The third objective of this trial, which is to demonstrate that the developed treatment strategy improves the mean treatment eect of SOC by a prescribed margin, amounts to testing the null hypothesis H * 0 : 
whereμ jk is the MLE of µ jk under the constraint ∑ J j=1π j max 1≤k≤K µ jk ≤ γ, in whichπ j is the observed prevalence of biomarker class j at the Ith (i.e., terminal) analysis. With a prescribed type I error ofα, the
The computation of dα is described in Section 3.3.
3. Implementation and Simulation Studies
Comparison of adaptive randomization schemes
We rst present a simulation of the performance of the preceding group sequential trial in treating patients who have been accrued to the trial, and its performance with respect to the inferential objectives relevant to future patients will be studied in Section 3.4. The adaptive randomization rule in the second paragraph of Section 2.2, denoted by AR1, does not involve elimination in the subsequent paragraphs, which will be studied in Section 3.4 and 3.5. It is a group sequential modication of the fully sequential upper condence bound (UCB) allocation rule that has been shown to minimize asymptotically the regret in the multi-arm bandit problem, as we have noted earlier. Accordingly the simulation study will compare AR1, which uses ϵ = 0.1 in (2), against the benchmark UCB rule in the response rate of patients receiving each treatment (including the best and the worst) for each biomarker class. Note that AR1 is quite dierent from the Bayesian adaptive allocation rule in the BATTLE trial described in Section 2.1, which assumes a hierarchical Bayesian probit model on the response rate p jk of treatment k for biomarker class j and which uses randomization probabilities proportional to the posterior means of p jk for dierent treatments in each biomarker class. Since these posterior distributions, evaluated by Markov chain Monte Carlo methods, are too computationally intensive for replicating them many times in a simulation study, we follow [7] and replace the posterior mean at the ith interim analysis by the maximum likelihood estimatep jk between interim analyses i and i + 1, denoted AR2, is also considered for comparison. In addition, we follow [19] and choose δ ij = n
biomarker class j at interim analysis i.
The simulation study considers n = 1000 and the cases K = J = 3 in Table 1 and K = 4, J = 3 or 4 in Table 2 . In addition, it assumes I = 5 analyses (including the interim and nal analyses), with equal group 
S1
:
S3
Thus, each biomarker class has a unique best treatment that is substantially better than other treatments in S1, there are treatments with moderate eectiveness between the best one and the worst ones for each biomarker class in S2, and there is a treatment which is close to the best for each biomarker class in S3. Table 2 considers scenarios S4 and S5 that are similar to the scenario 1 and 2 of the rst simulation study of [7] , and another scenario S6 similar to that in the BATTLE trial with the RXR/CyclinD1 class (that has a small size) and the all-negative biomarker class removed.
S4
: The results for each scenario in Tables 1 and 2 are based on 10000 simulations. For each allocation rule, besides the overall mean response of the n = 1000 subjects, the tables also give in parentheses the mean number of each (j, k) category of subjects in biomarker class j receiving treatment k and the mean response rate in this category. For each scenario in both tables, AR1 outperforms AR2 in terms of the overall mean response and the expected number of subjects receiving the best treatment in each biomarker class. Moreover, the benchmark UCB rule outperforms the adaptive randomization rules as expected but is inappropriate for applications to clinical trials that require informed consent and have operational diculties in implementing fully sequential procedures.
Computation of a α
The threshold a α is determined by the constraint P (best treatment for some biomarker class is eliminated) ≤ α. Fix j and order the parameter conguration for the k treatments as θ j, [1] [2] , the event of eliminating the (unique) best treatment for biomarker class j is
Letting θ j, [2] approach θ j, [1] implies that we can use P * (A j ) to bound the probability that the best treatment for biomarker class j is eliminated, where P * is the probability measure satisfying θ j1 = · · · = θ jK for all 1 ≤ j ≤ J. Hence a α can be determined by
in which the last equality follows from the inclusion-exclusion principle and the independence of the events Table 1 Mean response rate and sample size (in parentheses) for scenarios S1-S3 involving For xed j, we can compute P * (A j ) in (5) by using recursive numerical integration as follows. Since 
where
The above probability can be computed by applying the central limit theorem to
has independent increments in i. In particular, for K = 3, the conditional distribution of
Therefore the right-hand side of (6) 
Computation of dα
To compute the constrained MLEμ jk , note that the constraint
in the µ jk . Since the log-likelihood function is concave, its maximizer (μ j1 , · · · ,μ jK ) subject to convex constraints can be computed by using constrained convex optimization solvers, such as fmincon with the interior-point option in MATLAB.
Since the function g (µ) = ∑ J j=1 π j max 1≤k≤K µ jk that denes the composite null hypothesis H * 0 is not smooth at the hyperplanes µ jk = µ jk I in the case J = 3 and equal randomization of n = 1000 subjects to K = 3 treatments with Bernoulli outcomes that have success rates p 11 = p 22 = p 33 = 0.7 = γ, p jk = 0.69 for j ̸ = k. Fig. 1 corresponds to the case (C1) with γ = 0.7 in Table 4 , for which we use corrections, due to Cherno [20] and Self and Liang [21] , of the χ 2 1 approximation to the null distribution of twice the GLR statistic for testing g (µ) = γ. Besides the central limit theorem, the main ingredient leading to the χ 2 1 approximation when g is smooth is the quadratic approximation of the GLR statistic around µ = µ o with g (µ o ) = γ. When the partial derivatives of g at µ o have jump discontinuities, creating a kink (local cone) of the type mentioned in [20] and [21] for the graph of the continuous function g near µ o , the central limit theorem leads to the following limiting distribution of twice the GLR:
where Z is multivariate standard normal, I
(
is the singular value decomposition of the Fisher information matrix, and C 0 is a cone with vertex at D 1/2 P ′ µ o ; see [21, p. 607] . In other words, the limiting distribution is the same as that of the GLR test H 0 : µ ∈ C 0 based on Z; see [20] . 
cannot be estimated consistently. Feder [22] has derived the distribution of twice GLR when µ o is within O p (1/ √ n) of the boundary g (µ * ) = γ, showing that it is basically a noncentral version of (8) . For the special case of H * 0 , we can use this result to derive the following conservative estimate of
Letk j = max k∈Kjμjk and letm j be the number of treatments k ∈ K j such thatμ jk ≥μ j,kj − δ j , where (1) and the rst paragraph of Section 3.1. Note that H *
which is ≥ max k∈K µ jk for any subset K of {1, · · · , K}. Hence, choosing K to be the subset K j of surviving treatments would lead to a conservative estimate of dα.
. Therefore, we compute dα somewhat conservatively by using Monte Carlo simulations of (8)
A simulation study of inferences for future patients
In this section we present a simulation study of the inferential procedures in Section 2.2 in the case of K = J = 3, with k = j being the best treatment for biomarker class j. We take α = 0.1 andα = 0.05. 
that the best treatment is not included in the recommended set of treatments for some biomarker class, which is analogous to type I error, and the analog
, which is the probability that the recommended set contains an inferior treatment with p jk ≤ p j,kj −δ for some j. Also given are p I,j = P (A j ) and p II,j = P
for each j. Table 3 gives the values of p I and p II , and also the expected size E |K j | of the recommended set of treatments for each biomarker class j, withδ = 0.1. Also given are the probabilities of rejecting H * 0 for dierent values of γ; in particular, the value γ = 0.7 corresponds to the type I error of the test. In addition, Table 3 also gives the mean response rate, overall and for each (j, k) category, as in Table 1 and 2. Each result is based on 10000 simulations. The advantages of the proposed group sequential over the traditional design, which does not have interim analysis and uses equal randomization, can be seen by comparing Table 3 with Table 4 that gives corresponding results for the traditional design. Note that the traditional design is a special case of the group sequential design in Section 2.2 with I = 1. Because equal randomization dilutes the sample size for the best treatment, the power of the GLR test of H * 0 in Table 4 is lower than that in Table 5 , while the overall response rate of patients in the trial is also substantially reduced as expected.
Is adaptive randomization really useful?
In their comparison of clinical trial designs with xed sample sizes for testing whether a new treatment is better than a control treatment, Korn and Freidlin [23] have found no benets in using (outcome-) adaptive Tables 3 and   4 . Note, however, that whereas Table 3 uses a group sequential design with I = 5 analyses and allows treatment elimination at each analysis, Table 4 uses a xed sample size design that corresponds to the case I = 1. Following [23] , it is natural to ask whether the advantages of the proposed design over the traditional design are mainly due to the group sequential feature that allows early termination of inferior treatments. We have therefore also tried the same group sequential design in conjunction with equal (instead of adaptive) randomization for the surviving treatments in each biomarker class. Note that the threshold a α for treatment elimination remains the same, irrespective of equal or adaptive randomization. Moreover, the rejection threshold dα for the group sequential GLR test with equal randomization can be determined in the same way as in Section 3.4. Comparison of Table 3 with Table 5 , which gives the corresponding results for the group sequential design with equal randomization, shows that the marked improvements of adaptive randomization (Table 3 ) over equal randomization (Table 4) are substantially diminished when a group sequential design with early termination of signicantly inferior treatments is used.
Discussion
The emerging eld of biomarker-guided personalized therapies is an exciting new direction in translational medicine and poses new challenges to designing and analyzing clinical trials for their development and validation. While traditional designs often require large sample sizes, adaptive Bayesian designs such as that used by BATTLE, which allows researchers to avoid being locked into a single, static protocol of the trial, can yield breakthroughs, as pointed out in an April 2010 editorial in Nature Reviews in Medicine on such designs. In the same issue of the journal, Ledford [24] comments on these adaptive designs: The approach has been controversial, but is catching on with both researchers and regulators as companies struggle to combat the nearly 50% failure rate of drugs in large, late-stage trials. The BATTLE trial, however, is not associated with new drug development that is funded by a pharmaceutical company. For new drug development, we have described in Section 1 biomarker-guided accrual design for phase III trials. These designs are indeed It is much simpler than the Bayesian adaptive randomization rule used in the BATTLE trial, and is also convenient to use in conjunction with GLR statistics for group sequential testing and frequentist inference.
The group sequential design has an additional advantage that the cut-points used to dene the biomarker classes do not have to be nalized until analyzing the data from the trial up to the time of the rst interim analysis. The choice of these cut-points is normally based on data from previous early-phase trials with relatively small sample sizes in the literature. For example, Kim et al. [11, pp. 51-52] describe the measurement technology used in the BATTLE trial and the biomarker scoring methods used to develop the classier. In particular, combined expression of cytoplasmic and membrane staining or expression of nuclear staining was examined for dierent proteins, and all expression was assessed using semiquantitative analysis of intensity and extension to derive a score ranging from 0 to 300, or expressed as a percentage for nuclear expression. Cytoplasmic and membrane expression scores >100 were considered positive for VEGF and VEGFR-2, and scores >200 were considered positive for RXRβ and RXRγ. Moreover, a nuclear score >30% was considered positive for RXRα, and a nuclear score >10% was considered positive for CyclinD1.
Such semiquantitative classication is unsupervised learning based on heuristics and convenience. A supervised learning approach is proposed for BATTLE-2, which will prespecify an extremely limited set of markers and will use the rst half of the study population (approximately 200 patients) to conduct prospective testing of biomarkers/signatures to guide the second half of the study (approximately 200 patients).
Jiang et al. [27] have proposed to use the results of a phase III trial for a secondary analysis to identify the cut-points for dening biomarker classes in a future study. The initial stage of the group sequential design in Section 2.2 can be augmented to incorporate supervised learning of the biomarker classier with cut-points chosen on the basis of clinical trial data up to the rst interim analysis, which is analogous to the secondary analysis proposed in [27] and also to the rst half of the BATTLE-2 design but is more exible. Note that the initial stage (prior to the rst interim analysis) uses equal randomization to the K treatments in the absence of a biomarker classier. This is equivalent to the hypothetical version of SOC in [7] , which is assumed to choose the treatments with equal probability. If one wants to test whether the BGS to be developed is signicantly better than this hypothetical version of SOC, then one already has clinical trial data of the SOC and does not need to rely on historical data. Therefore, in addition to its multiple objectives listed in Section 2.2, the group sequential trial design proposed herein can also be used to build the biomarker classiers on the basis of clinical trial data up to the rst interim analysis and even to gather actual data about the SOC. Its sample size should be large enough to accomplish these goals, but it can be funded as a POC trial to improve the eectiveness of existing treatments, as discussed in the preceding paragraph.
